KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Assets: 2018-2024

Historic Current Assets for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $338.0 million.

  • Esperion Therapeutics' Current Assets rose 17.20% to $360.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.5 million, marking a year-over-year increase of 17.20%. This contributed to the annual value of $338.0 million for FY2024, which is 68.10% up from last year.
  • Per Esperion Therapeutics' latest filing, its Current Assets stood at $338.0 million for FY2024, which was up 68.10% from $201.1 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Current Assets registered a high of $345.9 million during FY2020, and its lowest value of $201.1 million during FY2023.
  • For the 3-year period, Esperion Therapeutics' Current Assets averaged around $261.9 million, with its median value being $246.7 million (2022).
  • In the last 5 years, Esperion Therapeutics' Current Assets fell by 25.01% in 2022 and then surged by 68.10% in 2024.
  • Esperion Therapeutics' Current Assets (Yearly) stood at $345.9 million in 2020, then fell by 4.89% to $329.0 million in 2021, then decreased by 25.01% to $246.7 million in 2022, then fell by 18.49% to $201.1 million in 2023, then spiked by 68.10% to $338.0 million in 2024.